Abstract
Background The Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome (HIV/AIDS) remain a major public health concern in Ghana. Despite sustained progress in treatment and prevention, regional prevalence variations persist, driven by healthcare access, urbanization, and socio-economic factors. This study identifies trends and hotspots to guide effective HIV surveillance and control strategies in Ghana.
Methods A retrospective ecological study was conducted using secondary HIV data confirmed by laboratory testing, from Ghana’s District Health Information Management System (DHIMS2) for the period 2020 to 2024. HIV prevalence was calculated as the number of confirmed cases per 100,000 population, using denominators from the Ghana Statistical Service 2021 Population and Housing Census. Spatiotemporal variation in prevalence was visualized using choropleth maps. Global Moran’s Index examined whether overall spatial dependency existed, followed by local indicators of spatial association (LISA), comprising local Moran’s I and the Getis-Ord Gi* statistic, to identify local clusters, outliers, and hotspots or coldspots.
Results National HIV prevalence per 100,000 population rose from 0.68 in 2020 to 0.84 in 2024. The highest burden was in the southern and middle belt regions: Western North (2.16), Bono East (1.71), Eastern (1.30), Volta (1.06), and Ahafo (1.01). Northern regions remained consistently low throughout the study period, with Northern (0.32), Upper East (0.26), and Savannah (0.30) recording averages below 0.50 per 100,000. Global Moran’s Index indicated a dispersed pattern in 2020 (I = −0.43), spatially random pattern between 2021 and 2023, and weak positive spatial association in 2024 (I = 0.22).
Conclusions Regional disparity in HIV prevalence in Ghana is widening, with greater burden concentrated in the more urbanized southern regions. Interventions guided by surveillance data and tailored to specific regions, including strengthened testing infrastructure and a more equitable distribution of health resources, are needed to curb transmission and support Ghana’s HIV and AIDS control programme.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. Ethics committee approval was not required under relevant laws and institutional guidelines. Ethics approval was not required for this study because it involved secondary analysis of routinely collected, aggregated health information obtained from the Ghana District Health Information Management System (DHIMS2). The dataset contained aggregated regional counts and did not include individual-level identifiers or personally identifiable information. The study did not involve direct contact with, recruitment of, or intervention involving human participants. Data were analysed in accordance with applicable institutional and data-governance requirements for the use of routinely collected health information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. Ethics committee approval was not required under relevant laws and institutional guidelines. Ethics approval was not required for this study because it involved secondary analysis of routinely collected, aggregated health information obtained from the Ghana District Health Information Management System (DHIMS2). The dataset contained aggregated regional counts and did not include individual-level identifiers or personally identifiable information. The study did not involve direct contact with, recruitment of, or intervention involving human participants. Data were analysed in accordance with applicable institutional and data-governance requirements for the use of routinely collected health information.
